|
US3117142A
(en)
|
1961-03-01 |
1964-01-07 |
Roussel Uclaf |
Novel preparation of estradiol and estrone
|
|
US3169134A
(en)
|
1963-03-21 |
1965-02-09 |
Searle & Co |
2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
|
|
BE754111A
(fr)
|
1969-07-29 |
1971-01-29 |
Upjohn Co |
Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
|
|
US3943124A
(en)
|
1970-12-17 |
1976-03-09 |
Gordon Hanley Phillipps |
Chemical compounds
|
|
GB1430942A
(en)
|
1972-05-05 |
1976-04-07 |
Glaxo Lab Ltd |
21-substituted 3alpha-hydroxy pregnanes
|
|
US3983111A
(en)
|
1972-05-05 |
1976-09-28 |
Glaxo Laboratories Limited |
Steroidal anaesthetics of the pregnane and 19-norpregnane series
|
|
US3865939A
(en)
|
1973-02-23 |
1975-02-11 |
Procter & Gamble |
Edible oils having hypocholesterolemic properties
|
|
US4071625A
(en)
|
1974-05-13 |
1978-01-31 |
Richardson-Merrell Inc. |
19-Oxygenated-5α-androstanes for the enhancement of libido
|
|
US4192871A
(en)
|
1976-01-06 |
1980-03-11 |
Glaxo Laboratories Limited |
Chemical compounds
|
|
GB1570394A
(en)
|
1976-01-06 |
1980-07-02 |
Glaxo Lab Ltd |
11-acyloxy-3-hydroxy steroids
|
|
GB1581234A
(en)
|
1976-04-05 |
1980-12-10 |
Glaxo Operations Ltd |
11a - amino - 3a - hydroxysteroids
|
|
SE8600632D0
(sv)
|
1986-02-13 |
1986-02-13 |
Kabivitrum Ab |
Novel pharmaceutical composition
|
|
US5120723A
(en)
|
1987-08-25 |
1992-06-09 |
University Of Southern California |
Method, compositions, and compounds for modulating brain excitability
|
|
US5232917A
(en)
|
1987-08-25 |
1993-08-03 |
University Of Southern California |
Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
|
|
US5319115A
(en)
|
1987-08-25 |
1994-06-07 |
Cocensys Inc. |
Method for making 3α-hydroxy, 3β-substituted-pregnanes
|
|
US5719197A
(en)
|
1988-03-04 |
1998-02-17 |
Noven Pharmaceuticals, Inc. |
Compositions and methods for topical administration of pharmaceutically active agents
|
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
CA2118938A1
(en)
|
1991-09-13 |
1993-04-01 |
Kelvin W. Gee |
Novel gabaa receptor with steroid binding sites
|
|
JP4008024B2
(ja)
|
1993-05-24 |
2007-11-14 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
Ｇａｂａａレセプター複合体と相互作用させるための化合物
|
|
EP0656365B1
(en)
|
1993-12-02 |
1997-04-09 |
Akzo Nobel N.V. |
Substituted 2beta-morpholinoandrostane derivatives
|
|
DK1038880T3
(da)
|
1994-02-14 |
2008-03-03 |
Euro Celtique Sa |
Androstaner og pregnaner til allosterisk modulering af GABA-receptor
|
|
US5939545A
(en)
|
1994-02-14 |
1999-08-17 |
Cocensys, Inc. |
Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
|
|
KR100477070B1
(ko)
|
1994-03-25 |
2006-04-21 |
이소테크니카 인코포레이티드 |
중수소화작용에의한의약품의효능강화법
|
|
JP2002500616A
(ja)
|
1994-07-21 |
2002-01-08 |
ファルマシア・アンド・アップジョン・カンパニー |
神経学的に活性なアミノステロイド
|
|
BR9509764A
(pt)
|
1994-11-23 |
1998-07-07 |
Cocensys Inc |
Série androstano e pregnano para modulação alostérica de receptor de gaba
|
|
PT837874E
(pt)
|
1995-06-06 |
2005-03-31 |
Euro Celtique Sa |
Esteroides neuroactivos da serie androstano e pregnano
|
|
US6780853B1
(en)
|
1995-06-06 |
2004-08-24 |
Euro-Celtique S.A. |
Neuroactive steroids of the androstane and pregnane series
|
|
JP4313435B2
(ja)
|
1995-07-24 |
2009-08-12 |
トラスティーズ オブ ボストン ユニバーシティー |
プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制
|
|
AU3967297A
(en)
|
1996-08-01 |
1998-02-25 |
Cocensys, Inc. |
Use of gaba and nmda receptor ligands for the treatment of migraine headache
|
|
US7630757B2
(en)
|
1997-01-06 |
2009-12-08 |
Flint Hills Scientific Llc |
System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject
|
|
US6046177A
(en)
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
|
US5874418A
(en)
|
1997-05-05 |
1999-02-23 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
|
|
US6316613B1
(en)
|
1997-07-25 |
2001-11-13 |
Beckman Coulter, Inc. |
Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis
|
|
US6245757B1
(en)
|
1997-10-03 |
2001-06-12 |
Research Corporation Technologies, Inc. |
Use of progestins to treat ischemic event
|
|
CN1270718C
(zh)
|
1998-03-11 |
2006-08-23 |
托布乔恩·贝克斯托罗姆 |
表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用
|
|
US20020198174A1
(en)
|
2001-05-07 |
2002-12-26 |
Allergan Sales, Inc. |
Disinfecting and solubilizing steroid compositions
|
|
US6376531B1
(en)
|
1998-11-13 |
2002-04-23 |
Rupert Charles Bell |
Method of treatment using deuterium compounds
|
|
US20030236236A1
(en)
|
1999-06-30 |
2003-12-25 |
Feng-Jing Chen |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
|
AU775102B2
(en)
*
|
1999-09-13 |
2004-07-15 |
David M. Swope |
Composition and method for decreasing neurologic symptomatology
|
|
DK1104760T3
(da)
|
1999-12-03 |
2003-06-30 |
Pfizer Prod Inc |
Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
|
|
US6613308B2
(en)
|
2000-09-19 |
2003-09-02 |
Advanced Inhalation Research, Inc. |
Pulmonary delivery in treating disorders of the central nervous system
|
|
US20020072509A1
(en)
|
2000-10-11 |
2002-06-13 |
Stein Donald Gerald |
Methods for the treatment of a traumatic central nervous system injury
|
|
EP1216713A1
(en)
|
2000-12-20 |
2002-06-26 |
Schering Aktiengesellschaft |
Compositions of estrogen-cyclodextrin complexes
|
|
GR1003861B
(el)
|
2000-12-29 |
2002-04-11 |
|
Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
|
|
AU2002250064B2
(en)
|
2001-02-13 |
2008-01-17 |
University Of Florida Research Foundation, Inc. |
A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes
|
|
US20030055026A1
(en)
|
2001-04-17 |
2003-03-20 |
Dey L.P. |
Formoterol/steroid bronchodilating compositions and methods of use thereof
|
|
US20030032638A1
(en)
|
2001-05-24 |
2003-02-13 |
Kim John J. |
Delivery of benzodiazepines through an inhalation route
|
|
US7090830B2
(en)
|
2001-05-24 |
2006-08-15 |
Alexza Pharmaceuticals, Inc. |
Drug condensation aerosols and kits
|
|
JP4357842B2
(ja)
|
2001-05-24 |
2009-11-04 |
アレックザ ファーマシューティカルズ， インコーポレイテッド |
所定の吸入ルートによるアルプラゾラム、エスタゾラム、ミダゾラムまたはトリアゾラムの送出
|
|
JP2003063965A
(ja)
|
2001-06-13 |
2003-03-05 |
Otsuka Pharmaceut Factory Inc |
注射用シロスタゾール水性製剤
|
|
SE0104423D0
(sv)
*
|
2001-12-27 |
2001-12-27 |
Umecrine Ab |
Pregnane steroids and their use in the treatment of CNS disorders
|
|
JP2005519294A
(ja)
|
2002-01-14 |
2005-06-30 |
アンセル・ヘルスケア・プロダクツ・インコーポレーテッド |
磁気検出可能ラテックス物品
|
|
WO2004019953A1
(en)
|
2002-08-28 |
2004-03-11 |
Hollis-Eden Pharmaceuticals, Inc. |
Therapeutic treatment methods
|
|
US20040132826A1
(en)
*
|
2002-10-25 |
2004-07-08 |
Collegium Pharmaceutical, Inc. |
Modified release compositions of milnacipran
|
|
US9339508B2
(en)
|
2003-01-17 |
2016-05-17 |
Mapreg |
Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury
|
|
CA2527019A1
(en)
|
2003-05-29 |
2005-01-06 |
Washington University |
Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids
|
|
WO2005011612A2
(en)
|
2003-07-31 |
2005-02-10 |
The Research Foundation Of State University Of New York |
Alpha 4 beta 2 delta gaba-a receptors as a strategy for pms and alcoholism
|
|
GB0321607D0
(en)
|
2003-09-15 |
2003-10-15 |
Vectura Ltd |
Manufacture of pharmaceutical compositions
|
|
US20070020299A1
(en)
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
|
ATE497787T1
(de)
|
2004-03-12 |
2011-02-15 |
Cipla Ltd |
Sterilisationsprozess für steroide
|
|
WO2005105822A2
(en)
|
2004-04-23 |
2005-11-10 |
Euro-Celtique S.A. |
3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
|
|
EP1591455A1
(en)
*
|
2004-04-29 |
2005-11-02 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Essential tremor diagnostic and treatment
|
|
ITMI20041763A1
(it)
|
2004-09-16 |
2004-12-16 |
Altergon Sa |
Nuove formulazioni iniettabili contenenti progesterone
|
|
US20060063707A1
(en)
|
2004-09-17 |
2006-03-23 |
Lifelike Biomatic, Inc. |
Compositions for enhancing memory and methods therefor
|
|
WO2006037016A2
(en)
*
|
2004-09-27 |
2006-04-06 |
The Regents Of The University Of California |
Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
|
|
AU2005330504B2
(en)
|
2004-09-29 |
2010-10-28 |
Harbor Biosciences, Inc. |
Steroid analogs and characterization and treatment methods
|
|
EP2353590A1
(en)
|
2005-02-15 |
2011-08-10 |
Elan Pharma International Limited |
Aerosol and injectable formulations of nanoparticulate benzodiazepine
|
|
ATE499104T1
(de)
|
2005-03-24 |
2011-03-15 |
Univ Emory |
Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns
|
|
EP1868593A2
(en)
|
2005-04-07 |
2007-12-26 |
Hythiam, Inc. |
Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
|
|
US20110319386A1
(en)
|
2005-08-26 |
2011-12-29 |
Braincells Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
ES2812250T3
(es)
|
2005-11-28 |
2021-03-16 |
Marinus Pharmaceuticals Inc |
Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
|
|
US20070287931A1
(en)
|
2006-02-14 |
2007-12-13 |
Dilorenzo Daniel J |
Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
|
|
WO2008030651A1
(en)
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
US20090239942A1
(en)
|
2006-09-15 |
2009-09-24 |
Cloyd James C |
Topiramate Compositions and Methods of Making and Using the Same
|
|
US20090203658A1
(en)
|
2007-01-08 |
2009-08-13 |
Duke University |
Neuroactive steroid compositions and methods of use therefor
|
|
US20090074677A1
(en)
|
2007-01-08 |
2009-03-19 |
Duke University |
Neuroactive steroid compositions and methods of use therefor
|
|
US7813811B2
(en)
|
2007-02-08 |
2010-10-12 |
Neuropace, Inc. |
Refillable reservoir lead systems
|
|
KR20160065998A
(ko)
|
2007-04-11 |
2016-06-09 |
바이오마린 파머수티컬 인크. |
테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
|
|
US8530463B2
(en)
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
|
EP2167098B1
(en)
|
2007-06-11 |
2018-09-05 |
University Of Southern California |
Allopregnanolone in a method for enhancing neurological function (alzheimer disease)
|
|
CA2698172C
(en)
|
2007-06-15 |
2014-02-18 |
Cook, Kevin M. |
Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
|
|
GB0711948D0
(en)
|
2007-06-20 |
2007-08-01 |
Bionature E A Ltd |
Neurosteriod compounds
|
|
WO2009000038A1
(en)
|
2007-06-28 |
2008-12-31 |
Cnsbio Pty Ltd |
Combination methods and compositions for treatment of neuropathic pain
|
|
EP2254577A1
(en)
|
2007-12-26 |
2010-12-01 |
Eisai R&D Management Co., Ltd. |
Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
|
|
AU2008347005B2
(en)
|
2008-01-03 |
2013-10-03 |
Biomarin Pharmaceutical Inc. |
Pterin analog for treating BH4 responsive condition
|
|
US20090198145A1
(en)
|
2008-02-06 |
2009-08-06 |
Chow Harrison |
Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
|
|
US8729070B2
(en)
|
2008-02-20 |
2014-05-20 |
Targia Pharmaceuticals |
CNS pharmaceutical compositions and methods of use
|
|
WO2010063030A2
(en)
|
2008-11-30 |
2010-06-03 |
Feigelson, Daniel |
Dermal application of vasoconstrictors
|
|
CZ2008434A3
(cs)
|
2008-07-10 |
2009-12-09 |
Ústav organické chemie a biochemie Akademie ved CR, v. v. i. |
Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
|
|
ES2617873T3
(es)
|
2008-10-10 |
2017-06-20 |
Vm Discovery, Inc. |
Composiciones y métodos para tratar trastornos de alcoholismo, dolor y otras enfermedades
|
|
WO2010088409A2
(en)
|
2009-01-30 |
2010-08-05 |
Emory University |
Methods of neuroprotection using neuroprotective steroids and a vitamin d
|
|
WO2010107922A1
(en)
*
|
2009-03-17 |
2010-09-23 |
Duke University |
Neuroactive steroid compositions and methods of use for lowering cholesterol
|
|
US20110152840A1
(en)
|
2009-12-23 |
2011-06-23 |
Drugtech Corporation |
Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
|
|
CN102802635B
(zh)
|
2010-01-21 |
2014-07-30 |
吊桥药业有限公司 |
麻醉药制剂
|
|
US8747365B2
(en)
|
2010-11-03 |
2014-06-10 |
Sanofi-Aventis Deutschland Gmbh |
Needle cannula containing medicament
|
|
US20130309306A1
(en)
|
2010-12-01 |
2013-11-21 |
The Regents Of The University Of California |
Intrapulmonary benzodiazepine for the treatment and prevention of seizures
|
|
CZ201181A3
(cs)
|
2011-02-15 |
2012-09-12 |
Ústav organické chemie a biochemie Akademie ved CR, v.v.i. |
Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
|
|
US9388210B2
(en)
|
2011-02-25 |
2016-07-12 |
Washington University |
Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
|
|
FR2973031B1
(fr)
|
2011-03-23 |
2013-11-29 |
Univ Strasbourg |
Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
|
|
US9084797B2
(en)
|
2011-05-23 |
2015-07-21 |
Besins Healthcare Luxembourg Sarl |
Progesterone treatment for improving sleep quality
|
|
WO2013002584A2
(ko)
|
2011-06-28 |
2013-01-03 |
주식회사 비보존 |
다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
|
|
WO2013019711A2
(en)
|
2011-07-29 |
2013-02-07 |
The Regents Of The University Of California |
NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
|
|
HUE062616T2
(hu)
|
2011-09-08 |
2023-11-28 |
Sage Therapeutics Inc |
Neuroaktív szteroidok, készítmények és alkalmazásaik
|
|
US10478505B2
(en)
|
2011-09-23 |
2019-11-19 |
The Regents Of The University Of California |
Edible oils to enhance delivery of orally administered steroids
|
|
EP4717314A2
(en)
|
2011-10-14 |
2026-04-01 |
Sage Therapeutics, LLC |
3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
|
|
US9125926B2
(en)
|
2011-11-29 |
2015-09-08 |
Amino Up Chemical Co. Ltd |
Vicenin 2 and analogues thereof for use as an antispasmodic and/or prokinetic agent
|
|
SG10201606063RA
(en)
|
2012-01-23 |
2016-09-29 |
Sage Therapeutics Inc |
Neuroactive steroid formulations and methods of treating cns disorders
|
|
US20150175651A1
(en)
|
2012-06-15 |
2015-06-25 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
WO2014028398A2
(en)
|
2012-08-13 |
2014-02-20 |
The Regents Of The University Of California |
Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
|
|
RS62761B1
(sr)
|
2012-08-21 |
2022-01-31 |
Sage Therapeutics Inc |
Alopregnanolon za lečenje refraktornog epileptičkog statusa
|
|
US9765110B2
(en)
|
2012-10-08 |
2017-09-19 |
Washington University |
Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
|
|
WO2014071449A1
(en)
|
2012-11-09 |
2014-05-15 |
Goodchild Investments Pty Ltd |
Neuroactive steroids and their use to facilitate neuroprotection
|
|
US20150313915A1
(en)
|
2012-11-30 |
2015-11-05 |
The Regents Of The University Of California |
Anticonvulsant activity of steroids
|
|
DK2935307T3
(en)
|
2012-12-18 |
2018-07-30 |
Univ Washington |
NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS USED IN METHODS OF TREATMENT
|
|
WO2014108808A2
(en)
|
2013-01-09 |
2014-07-17 |
Henry James Lorne |
Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
|
|
SMT202100509T1
(it)
|
2013-04-17 |
2021-11-12 |
Sage Therapeutics Inc |
Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
|
|
US9725481B2
(en)
|
2013-04-17 |
2017-08-08 |
Sage Therapeutics, Inc. |
19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
|
|
CN117304245A
(zh)
|
2013-04-17 |
2023-12-29 |
萨奇治疗股份有限公司 |
刺激神经活性的19-去甲类固醇及其使用方法
|
|
WO2014169836A1
(en)
|
2013-04-17 |
2014-10-23 |
Sage Therapeutics, Inc. |
19-nor neuroactive steroids and methods of use thereof
|
|
CA2918735C
(en)
|
2013-07-19 |
2023-08-01 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
CN105579043B
(zh)
|
2013-08-23 |
2021-09-14 |
萨奇治疗股份有限公司 |
神经活性类固醇、组合物和其用途
|
|
SI3705488T1
(sl)
|
2014-05-29 |
2022-10-28 |
Sage Therapeutics, Inc. |
Nevroaktivni steroidi, sestavki in uporaba le-teh
|
|
US10246482B2
(en)
|
2014-06-18 |
2019-04-02 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
|
US20170233433A1
(en)
|
2014-10-16 |
2017-08-17 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
|
MY190408A
(en)
|
2014-10-16 |
2022-04-21 |
Sage Therapeutics Inc |
Compositions and methods for treating cns disorders
|
|
WO2016082789A1
(en)
|
2014-11-27 |
2016-06-02 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
|
LT3250210T
(lt)
|
2015-01-26 |
2021-04-12 |
Sage Therapeutics, Inc. |
Kompozicijos ir būdai, skirti gydyti cns sutrikimus
|
|
JP2018504420A
(ja)
|
2015-02-06 |
2018-02-15 |
マリナス ファーマシューティカルズ インコーポレイテッド |
静注用ガナキソロン製剤ならびにてんかん重積状態および他の発作性障害の治療におけるその使用
|
|
DK3258939T3
(da)
|
2015-02-20 |
2022-12-12 |
Sage Therapeutics Inc |
Neuroaktive steroider, sammensætninger og anvendelser heraf
|
|
EP3280420B1
(en)
|
2015-04-10 |
2024-03-27 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
|
AR105044A1
(es)
|
2015-06-18 |
2017-08-30 |
Sage Therapeutics Inc |
Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente
|
|
GB2541015A
(en)
|
2015-08-06 |
2017-02-08 |
Ge Oil & Gas Uk Ltd |
Subsea flying lead
|
|
AU2016338916B2
(en)
|
2015-10-14 |
2021-12-23 |
The Regents Of The University Of California |
Enhancing beta cell replication and/or survival
|
|
MA43284A
(fr)
|
2015-11-20 |
2018-09-26 |
Sage Therapeutics Inc |
Composés et leurs méthodes d'utilisation
|
|
PH12018501923B1
(en)
|
2016-03-08 |
2024-06-28 |
Sage Therapeutics Inc |
Neuroactive steroids, compositions, and uses thereof
|
|
WO2018013613A1
(en)
|
2016-07-11 |
2018-01-18 |
Sage Therapeutics, Inc. |
C17, c20, and c21 substituted neuroactive steroids and their methods of use
|
|
CA3030420C
(en)
|
2016-07-11 |
2025-11-18 |
Sage Therapeutics, Inc. |
C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
|
|
KR20230050474A
(ko)
|
2016-08-11 |
2023-04-14 |
오비드 테라퓨틱스 인크. |
간질 장애의 치료를 위한 방법 및 조성물
|
|
US20180050005A1
(en)
|
2016-08-16 |
2018-02-22 |
Janssen Pharmaceutica Nv |
Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
|
|
US20180050107A1
(en)
|
2016-08-16 |
2018-02-22 |
Janssen Pharmaceutica Nv |
Neurosteroid compositions and methods of use thereof
|
|
TW202604538A
(zh)
|
2016-08-23 |
2026-02-01 |
美商賽吉醫療公司 |
結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
|
|
EP3509585B1
(en)
|
2016-09-07 |
2023-11-01 |
Glia, LLC |
Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
|
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
|
WO2018169798A1
(en)
|
2017-03-11 |
2018-09-20 |
The Regents Of The University Of California |
Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers
|
|
EP3612186A1
(en)
|
2017-04-18 |
2020-02-26 |
Marinus Pharmaceuticals, Inc. |
Sustained release injectable neurosteroid formulations
|
|
US20180338959A1
(en)
|
2017-05-24 |
2018-11-29 |
Ovid Therapeutics Inc. |
Treatment of depressive disorders
|
|
US11752115B2
(en)
|
2017-06-21 |
2023-09-12 |
The Board Of Trustees Of The University Of Illinois |
PPAR-alpha agonist treatment of neuropsychiatric disorders
|
|
AU2018290348B2
(en)
|
2017-06-23 |
2024-04-04 |
Ayikoe-Guy MENSAH-NYAGAN |
Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
|
|
EP3642206A4
(en)
|
2017-06-23 |
2021-04-07 |
The Regents of The University of California |
INCREASED GABA ABILITY TO MODULATE IMMUNE REACTIONS
|
|
EP3678670A1
(en)
|
2017-09-07 |
2020-07-15 |
Sage Therapeutics, Inc. |
Neuroactive steroids and their methods of use
|
|
WO2019051477A1
(en)
|
2017-09-11 |
2019-03-14 |
Sage Therapeutics, Inc. |
METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION
|
|
US20220110949A1
(en)
|
2017-09-14 |
2022-04-14 |
Sage Therapeutics, Inc. |
A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
|
|
SG11202004329TA
(en)
|
2017-11-10 |
2020-06-29 |
Marinus Pharmaceuticals Inc |
Ganaxolone for use in treating genetic epileptic disoders
|
|
US20200291059A1
(en)
|
2017-12-08 |
2020-09-17 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
|
EP3728285B1
(en)
|
2017-12-22 |
2026-04-08 |
Sage Therapeutics, LLC |
Compositions and methods for treating cns disorders
|
|
CA3086299A1
(en)
|
2017-12-22 |
2019-06-27 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
|
JP7538040B2
(ja)
|
2018-01-12 |
2024-08-21 |
セージ セラピューティクス， インコーポレイテッド |
ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物
|
|
UY38213A
(es)
|
2018-05-04 |
2019-10-31 |
Acerus Pharmaceuticals Corp |
Derivados de neuroesteroides y usos de estos
|
|
WO2019241442A1
(en)
|
2018-06-12 |
2019-12-19 |
Sage Therapeutics, Inc. |
A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
|
|
AU2019357040B2
(en)
|
2018-10-12 |
2025-03-27 |
Sage Therapeutics, Inc. |
Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders
|
|
EP4606812A3
(en)
|
2018-10-19 |
2025-10-15 |
Sage Therapeutics, Inc. |
9(11)-unsaturated neuroactive steroids and their methods of use
|
|
US11311529B2
(en)
|
2018-11-08 |
2022-04-26 |
Varsona Therapeutics, Inc. |
Topical formulations of 5-α-reductase inhibitors and uses thereof
|
|
KR20210110585A
(ko)
|
2018-11-21 |
2021-09-08 |
썰테고 테라퓨틱스 아이엔씨. |
자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
|
|
IL312610B2
(en)
|
2018-12-05 |
2026-05-01 |
Sage Therapeutics Llc |
Neuroactive steroids and methods of using them
|
|
US11266662B2
(en)
|
2018-12-07 |
2022-03-08 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of postpartum depression
|
|
CN113365635A
(zh)
|
2018-12-14 |
2021-09-07 |
阿克罗斯生物制药公司 |
睾酮的活性酯衍生物、组合物和其用途
|
|
TWI848034B
(zh)
|
2018-12-21 |
2024-07-11 |
美商賽吉醫療公司 |
神經活性類固醇及其組合物
|
|
TWI855081B
(zh)
|
2019-05-24 |
2024-09-11 |
美商賽吉醫療公司 |
化合物、組合物及使用方法
|
|
JP7670626B2
(ja)
|
2019-05-31 |
2025-04-30 |
セージ セラピューティクス， インコーポレイテッド |
神経刺激性ステロイド及びその組成物
|
|
BR112021026447A2
(pt)
|
2019-06-27 |
2022-04-12 |
Sage Therapeutics Inc |
Composições e métodos para tratamento de distúrbios de cns
|
|
JP7787635B2
(ja)
|
2019-06-27 |
2025-12-17 |
セージ セラピューティクス， エルエルシー |
Ｃｎｓ障害を治療するための組成物及び方法
|
|
CA3143545A1
(en)
|
2019-06-27 |
2020-12-30 |
Sage Therapeutics, Inc. |
Compounds for treating cns disorders
|
|
US20230018765A1
(en)
|
2019-12-05 |
2023-01-19 |
Sage Therapeutics, Inc. |
A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
|
|
AU2021238346A1
(en)
|
2020-03-18 |
2022-09-29 |
Sage Therapeutics, Inc. |
Neuroactive steroids and their methods of use
|
|
CN115551514A
(zh)
|
2020-03-25 |
2022-12-30 |
萨奇治疗股份有限公司 |
用于治疗呼吸系统病症的药物的用途
|
|
CN115768781A
(zh)
|
2020-06-24 |
2023-03-07 |
萨奇治疗股份有限公司 |
3.α.-羟基,17.β.-C(O)-N-芳基取代的神经活性类固醇及其组合物
|
|
CA3187178A1
(en)
|
2020-07-20 |
2022-01-27 |
Sage Therapeutics, Inc. |
Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof
|
|
EP4251634A1
(en)
|
2020-11-25 |
2023-10-04 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
|
WO2022165017A1
(en)
|
2021-01-28 |
2022-08-04 |
Sage Therapeutics, Inc. |
Use of neuroactive steroids for treatment of sexual dysfunction
|
|
WO2022177718A1
(en)
|
2021-02-18 |
2022-08-25 |
Sage Therapeutics, Inc. |
Use of neuroactive steroid for treatment of sexual dysfunction
|
|
JP2024510436A
(ja)
|
2021-03-17 |
2024-03-07 |
セージ セラピューティクス， インコーポレイテッド |
大うつ病性障害の処置のための１９－ノルｃ３，３－２置換ｃ２１－ｎ－ピラゾリルステロイド
|
|
CN117897160A
(zh)
|
2021-04-12 |
2024-04-16 |
萨奇治疗股份有限公司 |
特发性震颤的治疗
|
|
MX2023012728A
(es)
|
2021-04-29 |
2023-11-08 |
Sage Therapeutics Inc |
Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante.
|
|
MX2023012727A
(es)
|
2021-04-29 |
2023-11-08 |
Sage Therapeutics Inc |
Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto.
|